

Protective Effect of the *Spilanthes acmella* Extract Against the Genotoxic Damage Induced by Cyproterone Acetate in Cultured Human Peripheral Blood Lymphocytes

¹Yasir Hasan Siddique, ¹Gulshan Ara, ²Mohammad Faisal and ¹Mohammad Afzal

¹Human Genetics and Toxicology Laboratory, Section of Genetics, Department of Zoology,
Faculty of Life Sciences, Aligarh Muslim University, Aligarh 202002, U.P., India

²Forest Entomology Division, Forest Research Institute, Dehradun 248006, U.K, India

Abstract: In the present study the effect of *Spilanthes acmella* extract was studied against the genotoxic damage induced by 30 μM of cyproterone acetate (CPA) in cultured human peripheral blood lymphocytes. The extract was evaluated at 1.02×10^{-4} , 2.125×10^{-4} and 3.15×10^{-4} and 4.17×10^{-4} g/ml of culture medium. The treatment of all the selected doses of *S. acmella* extract results in a significant dose dependent decrease in the genotoxic effect induced by the CPA treatment alone. The results suggests that the plant extract *per se* do not have genotoxic effect, but can modulate the effect of CPA in cultured human peripheral blood lymphocytes.

Key words: Cyproterone acetate • Human lymphocytes • Mitotic index • Chromosomal aberrations • Sister chromatid exchanges • Replication index • *Spilanthes acmella*

INTRODUCTION

Spilanthes acmella is a flowering herb belongs to a family Asteraceae [1]. It has been used traditionally as a medicine for toothache, headache and treatment of asthma, rheumatism, fever, sore throat and haemorrhoids [2]. The crude extract of the flower head of the plant shows a potent ovicidal, larvicidal and pupicidal activities [3].

Synthetic progestins are not only used in the treatment of sexual and metabolic disorders, but also in oral contraceptives formulations [4]. Earlier studies have shown that the synthetic progestins have DNA damaging potential in the presence or absence of metabolic activation [5-11] and their genotoxic effects can be reduced by the use of antioxidants and natural plant products [12-21]. In India, the majority of population uses traditional natural preparations derived from the plant materials for the treatment of various diseases and for that reason it becomes necessary to assess the modulating potential of the plants extract when associated with other substances. Cyproterone acetate (CPA) is not only a tumor initiating agent [22, 23], but also a genotoxic agent [23-25]. An increase in the genotoxicity is associated with

the increase in the risk of developing cancer [26]. Studies of genotoxicity and antigenotoxicity of natural plant extracts can help us to evaluate the safety and effectiveness of herbal health products [27]. In present work we have studied the effect of *Spilanthes acmella* extract against the genotoxic dose of CPA, in cultured human peripheral blood lymphocytes.

MATERIALS AND METHODS

Chemicals: Cyproterone acetate (CAS No: 427-1-0, Sigma); RPMI 1640, Fetal calf serum, Phytohaemagglutinin-M, antibiotic-antimycotic mixture (In vitrogen); Dimethylsulphoxide, 5-Bromo-2-deoxyuridine, Colchicine (SRL), India); Giemsa stain (Merck).

Extract Preparation: *S. acmella* leaves were collected from the nursery of Forest Research Institute (FRI), Dehradun (UK) and were air dried and ground to fine powder, Extraction was performed by soaking samples (30 gm of dry weight) in 300 ml of acetone for 8-10h at 40°C-60°C in Soxhlet's apparatus. After filtration, the excess of solvent was removed by rotatory evaporator.

Corresponding author: Yasir Hasan Siddique Human Genetics and Toxicology Laboratory, Section of Genetics, Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University, Aligarh 202002, U.P, India. E-mail: yasir_hasansiddique@rediffmail.com.

The extract concentrations of 1.075×10^{-4} , 2.127×10^{-4} , 3.15×10^{-4} and 4.17×10^{-4} g/ml of culture medium were established [18].

Human Lymphocyte Culture: Heparinized blood samples were collected from 10 healthy donors (5 males, 5 females, non-smokers, age range 20-25). Whole blood (0.5 ml) was added to 5 ml of culture medium (pH 6.8-7.0), supplemented with 10% fetal calf serum, 10% antibiotic-antimycotic mixture and 1% phytohaemagglutinin of the final volume of the cell culture [28]. The culture tubes were then placed in the incubator at 37°C for 24 h.

Chromosomal Aberration Analysis: Following a 24h, incubation, 30 µM of cyproterone acetate (dissolved in DMSO, 5 µl/ml) was given along with 1.075×10^{-4} , 2.127×10^{-4} , 3.15×10^{-4} and 4.17×10^{-4} g/ml of *S. acmella* extract of final dose of culture medium. The cells were allowed to incubate for the remaining 48h. Treatment of 0.2 ml of colchicine (0.2 µg/ml) was given to the culture tubes prior to 1 h of the harvesting. Cells were then centrifuged at 1000 rpm for 10 min. The supernatant was removed and 8 ml of prewarmed (37°C) 0.075M KCl (hypotonic solution) was added and the cells were re-suspended and incubated at 37°C for 15 min. The supernatant was removed after centrifugation at 1000 rpm for 10 min and subsequently 5 ml of chilled fixative was added. The fixative was removed by centrifugation and the procedure was repeated twice. To prepare slides, 3-5 drops of the fixed cell suspension were dropped on a clean slide and air dried. The slides were then stained with Giemsa solution in phosphate buffer (pH 6.8) for 15 min. The slides were coded before scoring and approximately 50 metaphases were scored for chromosomal aberrations per dose per treatment per donor according to the recommendations of EHC 51 for short term test for mutagenic and carcinogenic chemicals [29].

Sister Chromatid Exchange Analysis: Bromodeoxyuridine (BrdU, 10 µg/ml) was added at the beginning of the culture. After 24 h, 30 µM of cyproterone acetate (dissolved in DMSO, 5 µl/ml) was given along with 1.075×10^{-4} , 2.127×10^{-4} , 3.15×10^{-4} and 4.17×10^{-4} g/ml of *S. acmella* extract. The cells were kept for the remaining 48h. Mitotic arrest was subsequently triggered by the addition of 0.2 ml of colchicine (0.2 µg/ml). Hypotonic treatment and fixation were performed in the same way as previously described for the chromosomal aberration analysis. The slides were coded before scoring and the sister chromatid exchange average was calculated from an

analysis of metaphases during the second cycle of division [30]. A total of 25 well spread and complete (2n=46) second division metaphases were scored per dose per treatment per donor. The frequency of SCE/chromosome was recorded according to Carrano and Natarajan [31].

Mitotic Index (MI) and Cell Cycle Kinetics (CCK):

The mitotic index was calculated as the number of metaphases in 1500 cells analysed per culture for each dose a group and donor. At least 100 metaphases per culture for each dose group and donor were scored to calculate the replication index. Metaphase divisions were detected by the BrdU-Harlequin technique for differential staining of metaphase chromosomes [32-33]. The replication index (RI), indirect measure of studying cell cycle progression was calculated by applying the following formula:

$$RI = \frac{M_1 + 2M_2 + 3M_3}{100}$$

Where M_1 , M_2 and M_3 denote the number of metaphases in the first, second and third cycle, respectively.

Statistical Analysis: Statistical analysis was performed by one way analysis of variance (ANOVA) and to study the dose responses the regression analysis was also performed by using commercial, software programme Stat Soft Inc.

RESULTS

The results of the present study reveal that the doses of *S. acmella* extract are not genotoxic itself, but reduce the genotoxic effects of cyproterone acetate. A significant dose dependent decrease in the chromosomal aberration per cell was observed when the treatment of 30 µM of CPA was given along with the different doses of *S. acmella* extract i.e. 1.075×10^{-4} , 2.127×10^{-4} , 3.15×10^{-4} and 4.17×10^{-4} g/ml (Table 1). A significant dose dependent increase in the mitotic index was also observed when the treatment of 30 µM of CPA was given along with the different doses of *S. acmella* extract i.e. 1.075×10^{-4} , 2.127×10^{-4} , 3.15×10^{-4} and 4.17×10^{-4} g/ml (Table 1). The treatment of 30 µM of CPA results in the significant increase in the frequency of SCEs/chromosome as compared to the untreated (Table 2). The treatment of the different doses of the extract of *S. acmella* with the 30 µM of CPA results in the significant dose dependent decrease in the frequency of SCE/chromosome (Table 2).

Table 1: Effect of *Spilanthes acmella* extract on chromosomal aberrations and mitotic index induced by Cyproterone acetate

Treatment	MI±SE	Chromosomal abnormalities									TCA/cell ±SE	
		CB	ICB	CG	ICG	CA	ICA	CE	P	DS		
CPA (µM)												
30	2.74±0.49 ^a	35	25	19	16	13	3	1	5	3	0.240±0.103 ^a	
CPA (µM) + SAE(g/ml)												
30+1.075x10 ⁻⁴	3.84±0.62 ^b	20	13	10	9	6	0	0	0	0	0.116±0.083 ^b	
30+2.125x10 ⁻⁴	3.98±0.65 ^b	17	12	9	7	5	0	0	0	0	0.100±0.072 ^b	
30+3.15x10 ⁻⁴	4.01±0.69 ^b	15	10	9	6	5	0	0	0	0	0.090±0.006 ^b	
30+4.17x10 ⁻⁴	4.27±0.71 ^b	14	8	7	5	3	0	0	0	0	0.074±0.003 ^b	
SAE (g/ml)												
1.075x10 ⁻⁴	4.59±0.82	9	7	8	7	6	0	0	0	0	0.074±0.003	
2.125x10 ⁻⁴	4.53±0.80	10	7	6	5	5	0	0	0	0	0.066±0.002	
3.15x10 ⁻⁴	4.50±0.73	11	6	6	5	6	0	0	0	0	0.068±0.002	
4.17x10 ⁻⁴	4.56±0.84	11	6	5	4	5	0	0	0	0	0.062±0.001	
Untreated	4.80±0.90	8	5	5	4	6	0	0	0	0	0.056±0.001	
Negative control (DMSO)	4.76±0.90 ^a	9	6	5	5	4	0	0	0	0	0.058±0.001	
Positive control (MMC)	1.36±0.19 ^a	125	73	30	25	57	30	30	10	7	0.774±0.542 ^a	

A total of 500 cells were scored for chromosomal aberrations.

^aP<0.005 significantly different from the untreated.

^bP<0.005 significantly different from the CPA.

CB: Chromatid break; ICB: Isochromatid break; CG: Chromatid gap; ICG: Isochromatid gap; CA: Chromosome acentric fragment; ICA: Isochromatid acentric fragment; CE: Chromatid exchange; P: Pulverization; DS: Dicentric chromosome; DMSO: Dimethyl sulphoxide (5µl/ml); MMC: mitomycin C (0.3 µg/ml) CPA: Cyproterone acetate; SAE: *Spilanthes acmella* extract.

Table 2: Effects of *Spilanthes acmella* extract on sister chromatid exchanges (SCEs) and replication index by Cyproterone acetate

Treatments	SCE/Chromosome±SE	RI±SE
CPA (µM)		
30	0.24±0.088 ^a	1.61±0.36 ^a
CPA (µM) + SAE(g/ml)		
30+1.075x10 ⁻⁴	0.18±0.073 ^b	1.73±0.60 ^b
30+2.125x10 ⁻⁴	0.16±0.065 ^b	1.75±0.62 ^b
30+3.15x10 ⁻⁴	0.15±0.061 ^b	1.76±0.64 ^b
30+4.17x10 ⁻⁴	0.13±0.056 ^b	1.78±0.67 ^b
SAE (g/ml)		
1.075x10 ⁻⁴	0.10±0.036	1.89±0.80
2.125x10 ⁻⁴	0.11±0.043	1.87±0.74
3.15x10 ⁻⁴	0.11±0.040	1.86±0.72
4.17x10 ⁻⁴	0.12±0.045	1.86±0.70
Untreated	0.09±0.021	1.94±0.89
Negative control (DMSO)	0.08±0.016	1.90±0.82
Positive control (MMC)	1.13±0.18 ^a	1.34±0.16 ^a

A total of 250 cells were scored for the SCE analysis and 100 cells were scored for RI

^aP<0.005 significantly different from the untreated.

^bP<0.005 significantly different from the cyproterone acetate.

CPA: Cyproterone acetate; SAE: *Spilanthes acmella* extract; DMSO: Dimethyl sulphoxide (5µl/ml); MMC: mitomycin C (0.3 µg/ml)




Fig. 1: Effect of *Spilanthes acmella* extract on the chromosomal aberrations per cell after the treatment along with 30 µM of Cyproterone acetate. The concentration of the extract is in (X 10⁻⁴ g/ml).




Fig. 2: Effect of *Spilanthes acmella* extract on the sister chromatid exchange per chromosome after the treatment along with 30 μ M of Cyproterone acetate. The concentration of the extract is in (X 10⁻⁴ g/ml).




Fig. 3: Effect of *Spilanthes acmella* extract on the mitotic index after the treatment along with 30 μ M of Cyproterone acetate. The concentration of the extract is in (X 10⁻⁴ g/ml).




Fig. 4: Effect of *Spilanthes acmella* extract on the replication index after the treatment along with 30 μ M of Cyproterone acetate. The concentration of the extract is in (X 10⁻⁴ g/ml).

The treatment of 30 μ M of CPA results in the decrease in the replication index as compared to untreated (Table 2). A significant dose dependent increase in the replication index was observed when 30 μ M of CPA treatment was given along with the different

doses of the *S. acmella* extract (Table 2). Regression analysis was also performed to determine the dose effect of *S. acmella* extract on 30 μ M of CPA, for mitotic index, chromosomal aberrations, sister chromatid exchanges and replication index. A decrease in

the slope of linear regression lines for chromosomal aberrations ($F=161.09$, $P<0.0005$) and sister chromatid exchange per chromosome ($F=93.62$; $P<0.0006$) was observed as the dose of the *S. acmella* extract was increased (Fig. 1 and 2). An increase in the slope of linear regression lines for mitotic index ($F=14.43$; $P<0.0007$) and replication index ($F=93.62$; $P<0.0001$) was observed as the dose of the *S. acmella* extract was increased (Fig. 3 and 4).

DISCUSSION

Our earlier study with cyproterone acetate shows that the generation of reactive oxygen species is responsible for the genotoxicity in cultured human peripheral blood lymphocytes [9]. The extract of *S. acmella* contain spilanthal, isobutylamide derivatives [34], α - and β -amyrin esters, stigmaterol, myricyl alcohol including sitosterol glucosides [35] and triterpenoid saponins [36]. Besides the main active component spilanthal of *Spilanthes acmella* it has also stigmasteryl-3- α - β -D-glucopyranoside [37]. Identification and characterization of the active principles in the plant extract may lead to the strategies to reduce the risk for developing cancer in human [38]. The data obtained in the present study suggest that the compounds present in the extract of *S. acmella* are not genotoxic itself, but can reduce the genotoxicity of CPA in cultured human blood lymphocytes. The reduction in the genotoxicity of CPA by *S. acmella* extract is possibly due to the direct action of the compounds present in the extract that can scavenge the reactive oxygen species and thereby prevents the genotoxic damage of CPA. The compounds present in the extract may scavenge electrophiles/nucleophiles [39] or they may enhance the DNA repair system or DNA synthesis or even may prevent the bio-activation of certain chemicals [40]. The compounds present in the extract may act synergistically as compared to the compound in isolation, as is evident in the present study and this supports the indigenous system of medicine namely Ayurvedic, Siddha and Unani, that have been in existence from centuries [1]. Hence, the present study also gives an indication that the extract of *S. acmella* may reduce the chances of having tumors in the patients undergoing CPA therapy. The identification and characterization of the compounds present in the *S. acmella* extract to determine their particular function will be the part of our future study.

ACKNOWLEDGEMENTS

We would like to thank DST, New Delhi for awarding the project No. SR/FT/LS-003/2007 under SERC-Fast Track Scheme to Dr. Yasir Hasan Siddique. We would also like to thank the Chairman, Department of Zoology, AMU, Aligarh, U.P., for the use of laboratory facilities.

REFERENCES

1. Chitravadivu, C., S. Manian and K. Kalaichelvi, 2009. Quantitative analysis of selected medicinal plants, TamilNadu, India. Middle East J. Sci. Res., 4: 144-146.
2. Ratnasooriya, W.D., K.P. Pieris, U. Samarantunga and J.R. Jayakody, 2004. Diuretic activity of *Spilanthes acmella* flowers in rats. J. Ethnopharmacol., 91: 317-320.
3. Saraf, D.K. and V.K. Dixit, 2002. *Spilanthes acmella* Murr. Study on its extract spilanthal as laticidal compound. Asian J. Exp. Sci., 16: 9-19.
4. IARC., 1999. International Agency for Research on Cancer, Oral Contraceptives, Combined (Group 1), 72: 49.
5. Joosten, H.F.P., F.A.A. Van Acker, Van de Dobbelsten, D.J. Horbach and E.I. Kranjc, 2004. Genotoxicity of hormonal steroids. Toxicol. Lett., 151: 113-134.
6. Siddique, Y.H. and M. Afzal, 2004. Evaluation of genotoxic potential of synthetic progestin chlormadinone acetate. Toxicol. Lett., 153: 221-225.
7. Siddique, Y.H. and M. Afzal. 2004. Evaluation of genotoxic potential of ethynodiol diacetate in human lymphocytes *in vitro*. Curr. Sci., 86: 1161-1165.
8. Siddique, Y.H. and M. Afzal, 2004. Induction of chromosomal aberrations and sister chromatid exchanges by chlormadinone acetate: a possible role of reactive oxygen species. Indian J. Exp. Biol., 42: 1078-1083.
9. Siddique, Y.H. and M. Afzal, 2005. Genotoxic potential of cyproterone acetate: a possible role of reactive oxygen species. Toxicol. *in vitro*, 19: 63-68.
10. Siddique, Y.H. and M. Afzal, 2005. *In vivo* evaluation of sister chromatid exchanges (SCEs) and chromosomal aberrations (CAs) by lynestrenol. Indian J. Exp. Biol., 43: 291-293.
11. Siddique, Y.H., G. Ara, T. Beg and M. Afzal, 2006. Genotoxic potential of medroxyprogesterone acetate in cultured human peripheral blood lymphocytes. Life Sci., 80: 212-218.

12. Siddique, Y.H. and M. Afzal, 2005. Protective role of allicin and L-ascorbic acid against the genotoxic damage induced by chlormadinone acetate in cultured human lymphocytes. *Indian J. Exp. Biol.*, 43: 769-772.
13. Siddique, Y.H., G. Ara, T. Beg and M. Afzal, 2007. Antigenotoxic effect of *Ocimum sanctum* L. extract against cyproterone acetate induced genotoxic damage in cultured mammalian cell. *Acta Biol. Hung.*, 58: 397-409.
14. Siddique, Y.H., G. Ara, T. Beg and M. Afzal, 2007. Protective role of nordihydroguaiaretic acid (NDGA) against the genotoxic damage induced by ethynodiol diacetate in human lymphocytes *in vitro*. *J. Environ. Biol.*, 28: 279-282.
15. Siddique, Y.H., G. Ara, T. Beg and M. Afzal, 2008. Antigenotoxic effect of nordihydroguaiaretic acid (NDGA) against chlormadinone acetate induced genotoxic damage in mice bone marrow cells. *J. Nat. Med.*, 62: 52-56.
16. Siddique, Y.H., G. Ara, T. Beg and M. Afzal, 2008. Possible modulation action of plant infusion of *Ocimum sanctum* L. on chromosomal aberrations and sister chromatid exchanges induced by chlormadinone acetate in human lymphocytes *in vitro*. *J. Environ. Biol.*, 29: 845-848.
17. Siddique, Y.H., G. Ara, T. Beg and M. Afzal, 2010. Anticlastogenic effect of apigenin in human lymphocytes treated with ethinylestradiol. *Fitoterapia* 81: 590-594.
18. Siddique, Y.H., G. Ara, T. Beg, M. Faisal, M. Ahmad and M. Afzal, 2008. Antigenotoxic role of *Centella asiatica* L. extract against cyproterone acetate induced genotoxic damage in cultured human lymphocytes. *Toxicol. in vitro*, 22: 10-17.
19. Siddique, Y.H., T. Beg and M. Afzal, 2005. Antigenotoxic effects of ascorbic acid against megestrol acetate induced genotoxicity in mice. *Hum. Exp. Toxicol.*, 24: 121-127.
20. Siddique, Y.H., Beg, T. and M. Afzal, 2006. Protective effect of nordihydroguaiaretic acid (NDGA) against norgestrel induced genotoxic damage. *Toxicol. in vitro*, 20: 227-233.
21. Siddique, Y.H. and M. Afzal, 2005. Antigenotoxic effect of allicin against methylmethane sulphonate induced genotoxic damage. *J. Environ. Biol.*, 26: 547-550.
22. Deml, E., L.R. Schwarz and D. Oesterle, 1993. Initiation of enzyme altered foci by the synthetic steroid cyproterone acetate in rat liver foci bioassay. *Carcinogenesis*, 14: 1229-1231.
23. Martelli, A., G.B. Campart, N. Ghia, A. Allavena, E. Mereto and G. Brambilla, 1996. Induction of micronuclei and initiation of enzyme altered foci in the liver of female rats treated with cyproterone acetate, chlormadinone acetate, or megestrol acetate. *Carcinogenesis*, 17: 551-554.
24. Kasper, P. and L. Mueller, 1999. Sex specific induction of apoptosis by cyproterone acetate in primary rat hepatocytes. *Carcinogenesis*, 20: 2185-2188.
25. Reimann, R., S. Kalweit and R. Lang, 1996. Studies for a genotoxic potential of some endogenous and exogenous sex steroid. II. Communication: Examination for the induction of cytogenetic damage using the chromosomal aberration assay on human lymphocytes *in vitro* and the mouse bone marrow micronucleus test *in vivo*. *Environ. Mol. Mutagen.*, 28: 133-144.
26. Hagmar, L., S. Bonassi, U. Stromberg, A. Brogger, J.E. Knudson, H. Norppa and C. Reuterwall, 1998. Chromosomal aberrations in human lymphocytes predict human cancer: A report from the European Study Group on cytogenetic biomarkers and health (ESCH). *Cancer Res.*, 58: 4113-4121.
27. Romero-Jimenez, M., J.C. Sanchez, M. Analla, A.M. Serrano and A.A. Moraga, 2005. Genotoxicity and antigenotoxicity of some traditional medicinal herbs. *Mutat. Res.*, 585: 147-155.
28. Carballo, M.A., S. Alvarez and S. Boveris, 1993. Cellular stress by light and Rose Bengal in human lymphocytes. *Mutat. Res.*, 288: 215-222.
29. IPCS. 1985. International Programme on Chemical Safety: Environmental Health Criteria 46. Guidelines for the study of genetic effects in human populations, WHO, Geneva, pp: 25-54.
30. Perry, P. and S. Wolff, 1974. New Giemsa methods for differential staining of sister chromatids. *Nature*, 261: 156-158.
31. Carrano, A.V. and A.T. Natarajan, 1988. Consideration for population monitoring using cytogenetic technique, ICPEMC Publication No. 14, International Commission for protection against Environmental Mutagens and Carcinogens. *Mutat. Res.*, 204: 379-406.

32. Crossen, P.E. and M.F. Morgan, 1977. Analysis of human lymphocyte cell cycle time in culture measures by sister chromatid differential staining. *Exp. Cell Res.*, 104: 453-457.
33. Tice, R.R., Schneider, E.L. and J.M. Rary, 1976. The utilization of bromodeoxyuridine incorporation in DNA for the analysis of cellular kinetics. *Exp. Cell Res.*, 102: 232-236.
34. Ramsevak, R.S., A.J. Erickson and M.G. Nair, 1999. Bioactive N-isobutylamides from the flower buds of *Spilanthes acmella*. *Phytochemistry*, 51: 729-732.
35. Wongsawatkul, O., S. Prachayasittikul, C. Isarankura-Na-Ayudhya, J. Satayavivad, S. Ruchirawat and V. Prachayasittikul, 2008. Vasorelaxant and antioxidant activity of *Spilanthes acmella* Murr. *Int. J. Mol. Sci.*, 9: 2724-2744.
36. Mukharya, D.K. and A.H. Ansari, 1987. Olean-12-en-3-o-beta-D-galactopyranosyl (1→4)-o-alpha-L-rhamnopyranoside: A new triterpenoidal saponin from the roots of *Spilanthes acmella* (Murr.). *Indian J. Chem., B*, 26: 86.
37. Ley, J.P., M. Blings, G. Krammer, G. Reinders, C.O. Schmidt and H.J. Bertam, 2006. Isolation and synthesis of acmellonate, a new unsaturated long chain 2-ketol ester from *Spilanthes acmella*. *Nat. Proc. Res.*, 20: 798-804.
38. Dearfield, K.L., M.C. Cimino, N.E. Mc Carroll, I. Mauer and L.R. Valcovic, 2002. Genotoxicity risk assessment: a proposed classification strategy. *Mutat. Res.*, 521: 121-125.
39. Maurich, T., L. Pistelli and G. Turchi, 2004. Anticlastogenic activity of two structurally related pterocarpanes purified from *Bituminaria bituminosa* in cultured human lymphocytes. *Mutat. Res.*, 561: 75-81.
40. Kuroda, Y., A.K. Jain, H. Tezuka and T. Kada, 1992. Antimutagenicity in cultured mammalian cells. *Mutat. Res.*, 267: 201-209.